Immix Biopharma announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The company intends to use the net proceeds from the proposed offering for NXC-201 clinical trials, working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners, is acting as sole book-running manager for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMMX:
- Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
- Immix Biopharma ‘applauds’ FDA labeling change notification for CAR-T products
- Three new option listings on January 24th
- Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
- Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
